Proteome Sciences PLC AGM Statement
May 16 2024 - 1:00AM
RNS Regulatory News
RNS Number : 6166O
Proteome Sciences PLC
16 May 2024
16 May 2024
Proteome Sciences
plc
("Proteome Sciences" or the
"Company")
Annual General Meeting
Statement
At the Company's Annual General
Meeting ("AGM") being held today at 12.00 noon, the Chairman,
Christopher Pearce, will make the following statement:
Since the start of 2024, we have
seen significant customer engagement and interest in proteomics
services reflected by the considerable increase in customer contact
and quotations provided, including the substantial contract win
from a US biopharmaceutical company announced on 26 April
2024.
The Company is confident and well
positioned to see the business return to growth in 2024, following
the launch of single cell proteomics ("SCP"), the introduction of
new next generation tags in the isobaric and isotopic field, and
the opening of the new facility in the USA during 2023 to provide
services locally.
For
further information:
Proteome Sciences plc
|
Dr. Mariola Soehngen, Chief
Executive Officer
Dr. Ian Pike, Chief Scientific
Officer
|
Tel: +44 (0)20 7043 2116
|
|
Richard Dennis, Chief Commercial
Officer
Abdelghani Omari, Chief Financial
Officer
|
|
|
|
|
|
Allenby Capital Limited (Nominated Adviser &
Broker)
|
|
John Depasquale / Lauren Wright
(Corporate Finance)
Tony Quirke / Stefano Aquilino
(Equity Sales & Corporate Broking)
|
Tel: +44 (0) 20 3328 5656
|
|
|
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a
specialist provider of contract proteomics services to enable drug
discovery, development and biomarker identification, and employs
proprietary workflows for the optimum analysis of tissues, cells
and body fluids. SysQuant® and TMT®MS2 are unbiased methods for
identifying and contextualising new targets and defining mechanisms
of biological activity, while analysis using Super-Depletion and
TMTcalibrator™ provides access to over 8,500 circulating plasma
proteins for the discovery of disease-related biomarkers. Targeted
assay development using mass spectrometry delivers high
sensitivity, interference-free biomarker analyses in situations
where standard ELISA assays are not available.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
AGMAAMFTMTJBBFI
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Nov 2023 to Nov 2024